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Background: Abdominal aortic aneurysm (AAA) is a prevalent health condition affecting up to 14% of men and 6% of
women. The objective of this study was to estimate the cost-effectiveness and cost-utility of elective endovascular
aneurysm repair (EVAR) compared with open surgical repair (OSR) in patients at a high risk of surgical complications.
Methods: Patient-level cost and outcome data from a 1-year prospective observational study conducted at London Health
Sciences Centre, London, Ontario, Canada, was used to determine the incremental cost per life-year gained and the
incremental cost per quality-adjusted life year (QALY) gained of EVAR compared with OSR in patients with an AAA
>5.5 cm and a high risk of surgical complications. The analysis was taken from a societal perspective and the time horizon
was 1 year. To measure sampling uncertainty on costs and effects, nonparametric bootstrap techniques were applied.
Uncertainty results were expressed using cost-effectiveness acceptability curves. Extrapolations of the 1-year results to a
5-year time horizon were conducted in sensitivity analyses.
Results: Between August 11, 2003, and April 3, 2005, 192 patients at a high risk of surgical complications were enrolled:
140 received EVAR and 52 OSR. Point estimates during a 1-year period showed that EVAR dominated OSR for
high-risk patients in terms of incremental cost per life-year gained and incremental cost per QALYs. However, bootstrap
estimates for the two cost-effectiveness measures indicated there was a great deal of uncertainty regarding the costs and
the QALYs and less uncertainty regarding life-years gained. If society was willing to pay $50,000 per life-year gained or
per QALY gained, the probability of EVAR being cost-effective was found to be 0.76 and 0.55, respectively. Five-year
extrapolations indicated that EVAR was cost-effective compared with OSR.
Conclusions: According to this 1-year observational study, EVAR may be a cost-effective strategy compared with OSR for
high-risk patients. Longer-term data are needed to decrease the uncertainty associated with the results. ( J Vasc Surg
2008;48:779-87.)Open surgical repair (OSR) is currently the primary
method of repair of abdominal aortic aneurysm (AAA) in
Canada; however, in some jurisdictions, endovascular an-
eurysm repair (EVAR) is becoming the predominate
method of managing AAA.1,2 The Canadian Society for
Vascular Surgery (CSVS) “recommends that EVAR should
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effective than OSR, several economic evaluations have been
conducted in recent decades. In 2007 for example, Jonk et
al4 reviewed 20 economic articles and concluded that com-
pared with OSR, EVAR was not cost-effective. However,
none of these studies evaluated the cost-effectiveness of
EVAR compared with OSR for patients at a high risk of
postoperative complications.
The recent economic evaluations conducted by Epstein
et al5 and Prinssen et al,6 both published in 2007, used
mainly data from the EVAR trial 1 (EVAR1) and Dutch
Randomized Endovascular Aneurysm Management
(DREAM) trials, respectively, and did not provide any new
information on the comparative value of EVAR and OSR in
high-risk patients. However, results of a 4-year nonran-
domized prospective trial conducted in Ireland among
high-risk patients recently suggested similar outcomes and
lower costs when EVAR in 66 patients was compared with
OSR in 52.7 Unfortunately, the uncertainty associated
with the data (eg, sampling variability) was not dealt with
in that study, which may limit our confidence in the
results. This article presents a Canadian cost-effective-
ness analysis of EVAR against OSR for patients at a high
surgical risk, using data from a 1-year observational study
conducted in Ontario at London Health Science Centre
(LHSC).
The LHSC Endovascular Program, launched in De-
cember 1997, has been previously described.8 The LHSC
endovascular team currently consists of four experienced
endovascular surgeons, a dedicated interventional radiolo-
gist, specially trained operating room nurses, anesthesiolo-
gists, and radiology technicians. The patients are initially
assessed by the vascular/endovascular surgeon, and the
preoperative planning for each patient is done by the sur-
geon and the radiologist.
Postoperatively, the patients are recovered in the regu-
lar postanesthetic recovery unit before being transferred to
the regular vascular surgery ward before discharge home. In
terms of postprocedural surveillance, EVAR patients have a
computed tomography (CT) scan and are seen by the
surgeon at 1, 3, 6, and 12 months postoperatively. No
routine follow-up is conducted with OSR patients beyond
a single postoperative visit at 4 to 6 weeks, unless necessary.
Indications for remedial therapy are a new type 1 endoleak,
type 3 endoleak, or a persistent type 2 endoleak with an
enlarging aneurysm sac.
Evaluation of three scoring systems for selecting pa-
tients for OSR or EVAR were recently reported on the basis
of 310 EVAR and 561 OSR patients who underwent
elective repair of an infrarenal aortic aneurysm, by the
LHSC team, from September 1999 to December 2004.9
The results of this retrospective database analyses con-
firmed that objective scoring systems may help identify
patients at a high risk for OSR but a low risk for EVAR and
patients who may not benefit from EVAR (low risk). The
following presents a cost-effectiveness analysis of EVAR
compared with OSR in high-risk patients using data from a1-year prospective observational study conducted at
LHSC.
METHODS
Study participants. All patients requiring elective re-
pair of an intact AAA5.5 cm were invited to participate in
this 1-year nonrandomized, prospective observational
study conducted at LHSC between August 11, 2003, and
April 3, 2005. The study was conducted on an intention-
to-treat principle, and received ethics approval by the Uni-
versity of Western Ontario Ethics Review Board, London,
Ontario, Canada.
Treatment algorithm. The method of intervention to
repair AAA was determined according to LHSC clinical
criteria for EVAR and OSR and by discussion with the
patient. Individuals not willing to accept surgical options
were offered best medical treatment. Patients considering
surgical options were evaluated, and their surgical risk and
suitability was assessed. Patients were considered high risk
according to the extent of their comorbidities, which were
objectively assessed using the American Society of Anes-
thesiologists (ASA) and Society for Vascular Surgery/
International Society for Cardiovascular Surgery (SVS/
ISCVS) score.10-12
According to this algorithm, the choice of EVAR or
OSR was presented as surgical options for patients anatom-
ically suitable for EVAR. The repair of AAAs was completed
using OSR for low-risk patients or high-risk patients not
anatomically suitable for EVAR. For comparability pur-
poses, only OSR high-risk patients were included in this
economic evaluation because all EVAR study patients were
high-risk patients.
Resource utilization and costs. The costs related to
the initial hospitalization were directly derived from the
LHSC patient-specific data-costing system. Procedural
costs (including the cost of the endograft) and nonproc-
edurally related costs were itemized. Subsequent postoper-
ative resource utilization data, such as hospital admissions,
physician visits, procedures, and medications, were ob-
tained for each patient at 30 days and every 3 months for 1
year through the administration of economic question-
naires administered by a study coordinator. To capture
productivity losses after AAA repair, patients were asked to
indicate the mean number of paid days they took off work
as well as the average number of hours of care provided by
others. Unit costs of health care resource utilization for the
initial hospitalization and diagnostic tests were derived
from the LHSC and from the Ontario Schedule of Benefits
for Physician Fees. Costs were expressed in 2006 Canadian
dollars. The Canadian average hourly wage was used to
determine the cost of productivity losses.13
Effectiveness measures. Vital status and cause of
death were collected during the 1-year study period. The
mean number of life-years during the 1-year study period
was estimated using Kaplan-Meier survival curves, and the
observed life-years for EVAR and OSR for high-risk pa-
tients were calculated as the area under each survival curve.
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regularly scheduled intervals using results from the Euro-
pean quality of life (EuroQol) instrument (EQ-5D), which
was included in the study questionnaires to measure health-
related quality of life. The EQ-5D includes a visual ana-
logue scale and five questions related to mobility, self-care,
usual activity, pain/discomfort, and anxiety/depression,
for which answers can be used to generate a utility value
ranging from 0 (death) to 1 (perfect health). Health utility
summary scores for the EQ-5D were estimated using the
quality-adjusted survival for EVAR and OSR in high-risk
patients by combining Kaplan-Meier survival curves with
utility estimates over time.
Because of the observational nature of this trial, regres-
sion techniques were used to adjust utilities to take into
account potential differences in the mean baseline utility
between EVAR and OSR. At each assessment point (dis-
charge, 1, 3, 6, 9, and 12 months), ordinary least squares
regressions were used to estimate the mean change in utility
from baseline for the two treatment groups. In each regres-
sion model (eg, 1, 3 months), patient-specific utility values
were used as the dependant variable. Patient baseline utility
value and a treatment indicator were used as independent
variables, allowing at each assessment point the calculation
of an estimate of the mean change from baseline. Utility
values were then calculated at each time period assuming a
common baseline utility value of 0.77 for each group, the
mean baseline utility value.
Cost-effectiveness and statistical analyses. Cost-
effectiveness analyses of EVAR compared with OSR were
performed in terms of incremental cost per life-year gained
and incremental cost per quality-adjusted life-year (QALY)
gained. Incremental cost-effectiveness ratios were not cal-
culated if one treatment strategy dominated the other (ie,
lower costs, better outcomes). The analysis was taken from
a societal perspective and the time horizon was 1 year.
To measure uncertainty on costs and effects due to
sampling variability associated with the trial, nonparametric
bootstrap techniques were applied allowing the calculations
of 95% confidence intervals (CIs). Bootstrapping consists
of drawing a sample with replacement and equal of size of
the original data set (eg, 140 for EVAR and 52 for OSR).
For this new sample, the mean costs and effects associated
with each group are calculated to derive the incremental
cost-effectiveness ratios. This process is repeated several
times (eg, hundreds of times) to determine the incremental
cost-effectiveness ratio and the 95% CIs associated with the
differences in costs and effects between EVAR and OSR.
The bootstrap differences in cost and effect pairs were also
plotted using a cost-effectiveness plane to get a better
understanding of the sampling distribution of the cost and
effect pairs of EVAR compared with OSR in high-risk
patients. Uncertainty results were also expressed using cost-
effectiveness acceptability curves to show for several thresh-
old values (eg, willingness to pay $100,000 to save 1 year of
life) the probability that EVAR is cost-effective compared
with OSR, when uncertainty is taken into account. To test
differences between the two groups in terms of baselinecharacteristics, costs and outcomes, statistical significance
was conducted using 2 tests for categoric variables and t
tests for continuous variables.
Sensitivity analyses. The long-term impact of the
lower operative mortality of EVAR on costs and outcomes
may be underestimated due to the 1-year time horizon of
the study; therefore, modeling techniques were used to
extend the time horizon 5 years in sensitivity analysis.
Because patients in the study may be at increased risk of
death compared with the general population, the 1-year
within-trial mortality rate for subjects alive after 30 days was
first compared with Canadian life tables of 75-year-old
Canadian men. According to this analysis, the risk of death
in study patients was 30% higher compared with the general
population of 75-year-old men. This relative risk (ie, 1.3)
was applied to the Statistics Canada mortality rates during
the course of the extrapolation to account for the increased
comorbidity and risk of death in the study population.
Routine follow-up costs for EVAR patients were as-
signed in the time horizon sensitivity analyses. From the
LHSC experience, it was assumed that EVAR patients
would have two CT scans and specialist consults annually
for the first 2 years after initial treatment and one CT scan
and specialist consult yearly thereafter. No routine follow-
up cost for OSR patients was assumed for the extrapola-
tions, according to LHSC clinical practice.
Reintervention rates of 5%, 10%, and 20% were applied
in sensitivity analyses assuming that 75% of reinterventions
would be embolizations and 25% would be complete
EVAR reinterventions, according to LHSC clinical experi-
ence. The average cost of embolization was assumed to be
$2000 on the basis of LHSC costs. The observed study
EVAR costs were assumed for the EVAR reinterventions.
The same utility rate was applied to both treatment groups
in the sensitivity analyses. The utility rate was set equal to
the lowest average observed 12-month utility rate between
EVAR and OSR patients. A discount rate of 5% was applied
to all costs and outcomes beyond 1 year.
The 5-year extrapolation analysis was run under three
mortality scenarios: (1) cumulative mortality converges
after 2 years; (2) cumulative mortality converges after 3
years; and (3) cumulative mortality converges after 5 years.
Specifically in these calculations, survival for EVAR patients
alive at the end of the trial was extrapolated over 5 years
using adjusted age-specific survival rates from Canadian life
tables. To run the three scenarios, the cumulative survival
rate for OSR patients was forced to converge to the cumu-
lative survival rate estimated for EVAR at 2 years (scenario
1), 3 years (scenario 2), and 5 years (scenario 3).
RESULTS
Patients and baseline characteristics. Between Au-
gust 11, 2003, and April 3, 2005, 351 patients with an
AAA 5.5 cm required elective AAA repair, and 342
patients participated in this study. Of the 192 patients
classified as high risk, 140 were treated with EVAR and 52
with OSR, of whom four (8%) were anatomically suitable
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best medical treatment.
As reported in Table I, the two groups were similar in
terms of age, smoking status, AAA diameter, SVS/ISCVS
score, ASA grade, history of myocardial infarction, conges-
tive heart failure (CHF), angina, renal function, and
chronic obstructive pulmonary disease (COPD). The Lei-
den Risk Score9 indicated they had a predicted mortality
rate of approximately 7%, and the two groups were compa-
rable (Table I). The proportion of EVAR procedures com-
pleted in men was greater (85.7% vs 73.1%, P  .04). The
EVAR and OSR patients were similar in other cardiac (eg,
valvular heart disease, 15.7% vs 9.6%; P  .28), vascular
characteristics (eg, stroke, 12.9% vs 5.8%; P  .16), and
diagnosed diabetes (eg, 19.3% vs 19.2%, P  .99).
Initial hospitalization and postoperative outcomes.
From admission to discharge, EVAR patients spent signif-
icantly less time in the hospital than OSR patients (7.7 days
vs 16.1 days, respectively), which was significant. Specifi-
cally, average lengths of stay were 7.0 days for EVAR and
11.2 days for OSR in the absence of postoperative compli-
cations and 16.7 days for EVAR and 24.0 days for OSR in
the presence of complications. Overall, the median length
of stay was 6 days for EVAR and 11 days OSR, and the
postoperative length of stay was 5.7 days for EVAR and
Table I. Baseline patient characteristics
Variable EVAR OSR Pa
Patients, No. 140 52
Age, mean (SD) years 75.6 (7.8) 74.0 (7.9) .24
Male gender, % 85.7 73.1 .04
Work full or part time, % 5.0 6.0 .73
Smoking status, % .07
Current 22.8 34.6
Ever 63.6 61.5
Never 13.6 3.9
AAA size, mean (SD) cm 6.2 (0.9) 6.5 (1.0) .10
SVS/ISCVS grade, % .97
I 34.3 34.6
II 65.7 65.4
ASA grade, % .69
I 0 0
II 1.4 0
III 32.1 33.3
IV 66.5 66.7
MI 6 months previous, % 2.1 3.9 .61
MI 6 months previous, % 43.9 40.4 .66
Congestive heart failure 9.3 9.6 .28
Angina 35.7 42.3 .40
Abnormal renal function 1.4 0 .99
COPD 35.7 41.2 .49
Leiden Score (raw), mean (SD) 9.8 (6.2) 7.8 (8.1) .10
Leiden Score (% predicted
mortality), mean (SD) 6.9 (4.3) 7.2 (10.0) .76
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiol-
ogists; COPD, chronic obstructive pulmonary disease; EVAR, endovascular
aneurysm repair; MI, myocardial infarction; OSR, open surgical repair;
SD, standard deviation; SVS/ISCVS, Society for Vascular Surgery/
International Society for Cardiovascular Surgery.
aEVAR vs OSR.14.4 for OSR. Intensive care unit admission was requiredfor 4% EVAR patients compared with 31% of OSR patients.
The 30-day mortality rates were 9.6% for OSR and 0.7% for
EVAR, and this difference was statistically significant. The
differences in postoperative complications were primarily
attributable to higher rates of complications in the OSR
group (Table II).
Resource utilization and costs. Table III presents
the total average 1-year cost of EVAR and OSR for high-
Table II. Initial hospitalization and postoperative
outcomes
Variable EVAR OSR P
Patient, No. 140 52
Initial hospitalization
LOS, mean (SD) days 7.7 (5.8) 16.1 (16.0) .01
LOS, median (range) days 6.0 (4-36) 11.0 (6-92)
ICU admission, % 3.6 30.8 .01
ICU LOS, mean (SD), days 0.2 (1.7) 3.2 (8.3) .01
Post-op complications
(30 days), %
Death 0.7 9.6 .01
Myocardial infarction 4.3 9.6 .17
CHF/pulmonary edema 3.4 17.3 .01
Arrhythmia 3.6 9.6 .14
Stroke 0.7 0 .99
Renal failure 3.6 11.5 .07
Pneumonia 0 7.7 .01
Sepsis 0 5.8 .02
CHF, Congestive heart failure; EVAR, endovascular aneurysm repair;
ICU, intensive care unit; LOS, length of stay; OSR, open surgical repair;
SD, standard deviation.
Table III. Total average 1-year costs by treatment group
Costs
EVAR
(n  140)
OSR
high-risk
(n  52)
EVAR
vs OSR
high-risk
Initial hospitalization costs
Procedural $18,326 $6162 $12,164a
Nonprocedural $9813 $25,029 $15,216a
Subtotals initial
hospitalization $28,139 $31,181 $3042
Follow-up medical costs
Hospital admissions $2318 $1250 $1069
Tests and procedures $1372 $90 $1282a
Emergency department $115 $38 $77
GP visits $349 $300 $49
Specialist visits $272 $145 $127a
Other health care
professionals $746 $348 $407
Subtotal follow-up cost $5172 $2171 $3010a
Total health care costs $33,311 $33,352 $32
Follow-up productivity costs
Mean paid days taken off
of work $523 $433 $90
Mean hours of care
provided by others $311 $385 $74
Subtotal $835 $818 $17
Total $34,146 $34,170 $24
EVAR, Endovascular aneurysm repair; OSR, open surgical repair.
aIndicates significance at the 5% level.risk patients by main categories, including initial hospital-
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costs. The total average initial costs of hospitalization were
$28,139 for EVAR and $31,181 for OSR, a difference not
statistically significant. Total average procedural costs, in-
cluding the cost of the endograft, were statistically signifi-
cantly higher for the EVAR patients ($18,326) then for the
OSR patients ($6162), mainly because EVAR patients
spent statistically less time in hospital than OSR patients
and had fewer complications. The average nonprocedurally
related costs were, however, statistically significantly
greater for the OSR patients ($25,029) then for the EVAR
patients ($9813).
In the absence of postoperative complications during
the initial hospitalization (EVAR, 131 of 140; OSR, 30 of
52), the mean hospitalization cost of EVAR was approxi-
mately $10,000 more than OSR in these high-risk patients
($26,985 vs $17,411), a difference close to the average cost
of the graft. Talent (W. L. Gore and Assoc, Flagstaff, Ariz)
and Zenith (Cook, Bloomington, Ind) grafts were used in
this study, with unit costs of $9600 to $10,200. In the
presence of postoperative complications, the costs associ-
ated with the initial hospitalization were similar between
OSR ($49,942) and EVAR ($44,942).
The average 1-year medical cost of follow-up was sta-
tistically higher in the EVAR group ($5181) than in the
OSR group ($2171), because of more frequent rehospital-
izations, tests, procedures, and physician visits in the EVAR
group. No reinterventions occurred within the 1-year study
period. One OSR patient required treatment for an abdom-
inal wall hernia. Indirect costs associated with days off work
and hours of care provided by others were estimated at
$837 for EVAR and $818 for OSR, which were 2% of the
total costs. Overall, the total 1-year costs were calculated at
$34,146 for EVAR and $34,170 for OSR high-risk pa-
tients, an almost negligible difference of $24.
Life-years gained. In our high-risk population, an
increased all-cause mortality rate of 17.3% was observed in
OSR patients compared with 7.1% in EVAR individuals at 1
year (P  .04). The estimated life-years gained, as deter-
mined from the Kaplan Meier survival curves, were 0.959
for EVAR and 0.848 for OSR high-risk patients (Fig 1).
Utilities and QALYs. When adjusted by baseline val-
ues, the patients’ EQ-5D utility was lower at discharge
compared with baseline utilities and then increased over
time for the two treatment groups, as shown in Fig 2, A.
However, although EVAR patients returned to a level
similar to their baseline values, the utilities after 1 year were
higher than the baseline values for OSR patients, as shown
in this figure. The resulting quality-adjusted survival curves,
when adjusted utilities over time were adjusted for survival
over time, are presented in Fig 2, B. The resulting QALYs
were calculated to be 0.713 for EVAR and 0.688 OSR
high-risk patients.
Cost-effectiveness results. The trial point estimates
indicated that EVAR has slightly a lower 1-year cost of $24
(Table III) and provides more benefits. However, the 95%
CIs associated with the differences in costs ranged from
–$11,582 to $9165 when calculated using bootstrap tech-niques. In terms of outcomes, EVAR had 0.111 more
life-years compared with OSR for high-risk patients (95%
CI, 0.022-0.213). More QALYs (0.025) were also associ-
ated with EVAR, but the differences were not statistically
significant (95% CI –0.075 to 0.128). On the basis of point
estimates only, EVAR dominated OSR in terms of incre-
mental cost per life-year gained and incremental cost per
QALYs (Table III). However, as indicated by the CIs, the
differences in the costs and QALYs were not significant at
the 5% level.
The 1-year costs and effects pairs generated by the
bootstrap resampling of the trial data are presented in Fig 3.
Here, costs are plotted on the y axis (“EVAR more/less
expensive”) against QALYs (Fig 3, A) or life-years gained
(Fig 3, B) represented on the x axis (“EVAR more/less
effective”). The origin represents OSR, the treatment of
reference. As shown by these cost-effectiveness planes,
there was considerable uncertainty regarding the costs and
the QALYs (Fig 3, A) and less uncertainty regarding life-
years gained (Fig 3, B) because there was an almost 100%
chance that EVAR would save additional lives compared
with OSR. For each quadrant of the cost-effectiveness
planes, the probability that EVAR was either dominant (less
costly and more effective), dominated (more costly and less
effective), or involved a trade-off vs OSR (more costly and
more expensive or less costly and less effective) is given
along with the bootstrap representation of uncertainty.
Each dot in these graphs represents a bootstrap sample.
Fig 4 presents the cost-effectiveness acceptability
curves for cost per life-year gained and QALY gained,
respectively. Not suggesting any particular threshold, but it
may be worthwhile to consider two commonly quoted
thresholds of $50,000 and $100,000 per QALY gained.14
The way to interpret these curves is to consider a threshold
that decision makers might be willing to pay for a unit of
effect, that is, willingness to pay per QALY gained, along
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Fig 1. Kaplan-Meier survival is shown for endovascular aneurysm
repair (EVAR, blue line) and open surgical repair (OSR, green line)
in high-risk patients at up to 365 days of follow-up.with the horizontal axis and read along the vertical axis the
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counting for uncertainty. If society was willing to pay
$50,000 per life-year gained, the probability of EVAR
being cost-effective was 0.76 compared with OSR in high-
risk patients (Fig 4, A). This probability increased to 0.9
when a threshold of $100,000/life-year gained was used.
In terms of incremental cost per QALY, the probability of
EVAR being cost-effective was lower, with probabilities of
0.55 and 0.58 when using thresholds of $50,000 and
$100,000, respectively (Fig 4, B).
Sensitivity analyses. The results of the sensitivity
analyses examining several mortality scenarios when the
data were extrapolated an additional 5 years indicated
that EVAR was cost-effective. The most favorable cost-
effectiveness occurs when it is assumed that survival con-
verges after 5 years and the EVAR reintervention rate was
5%. In this scenario the incremental cost-effectiveness ratios
of EVAR against OSR were $10,167/QALY gained and
$5584/life-year gained. The assumption least favorable to
EVAR was convergence of cumulative survival between
      Mean EQ-5D utility scores over time
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Fig 2. A, Mean utility scores for the EuroQol quality of life
instrument (EQ-5D) and (B) estimated quality-adjusted life-years
(QALYS) are shown for high-risk patients undergoing endovascu-
lar aneurysm repair (EVAR, blue lines) and open surgical repair
(OSR, green lines) during 365-days of follow-up.EVAR and OSR after 2 years along with a reinterventionrate of 20%. With this assumption, the incremental cost per
QALY gained and life-year gained were $38,720 and
$14,968, respectively.
DISCUSSION
In this 1-year observational study, a significant reduc-
tion in mortality was associated with EVAR compared with
OSR in patients at a high risk of surgical complications. The
30-day mortality rates observed in this study were compa-
rable with the rates reported in a recent review of random-
ized controlled trials for EVAR (0.7% vs 1.6%)15 but higher
for OSR (9.6% vs 4.7%),15 which may be caused by the
high-risk nature of the patients included in our study. Our
definition of high-risk patients was similar to the definition
used by Sicard et al16 in their analysis of high-risk patients
from the investigational device exemption trials, including
age 60 years, AAA 5.5 cm, and at least one of the
following comorbidities: symptomatic CHF, valvular heart
disease, cardiac arrhythmia, COPD, chronic renal failure,
or serum creatinine value 2.6 mg/dL. However, our
30-day and 1-year mortality rates were lower for EVAR and
higher for OSR. As noted by Nagpal et al,17 however, the
absence of a standardized reporting between studies of
high-risk patients makes comparisons difficult. Almost two-
third of patients in our study were at SVS/ISCVS grade II
and ASA grade 4. In both groups, the baseline Leiden
predicted mortality rate was 7%, which is also aligned with
the Canadian guidelines regarding the use of EVAR and the
definition of patients at an intermediate or high risk of risk
of postoperative morbidity or death (6% to 10%).
Although it is difficult to compare the findings of our
1-year prospective observational study with randomized
clinical trials of EVAR, the pattern of the utility scores over
time observed in our study (Fig 2, A) was similar to results
of the DREAM trial.6p886 When compared with the
DREAM trial, our results indicated that high-risk patients
undergoing EVAR experienced the same number of
QALYs (0.71 vs 0.72 in DREAM), whereas the OSR
population derived less QALYs (0.69 vs 0.72, respectively).
The QALY differences were not significant in either study.
Another Canadian study indicated no differences in health-
related quality of life between EVAR and OSR.18
Consistent with other evaluations, EVAR patients had
a shorter hospital and ICU length of stay than OSR pa-
tients. The relatively long length of stay observed in our
study is a reflection of the Ontario health system and the
high-risk patient population included in the study. In On-
tario and in Canada in general, postoperative care occurs
within the primary care setting, and transfer to rehabilita-
tion facilities is infrequent. An earlier study of 552 patients
undergoing nonelective or elective AAA repair in four
Canadian hospitals between 1997 and 2000 reported 90%
were discharged to self-care vs 66% for the United States
(US). Almost one-third of US patients were either dis-
charged to home care (16.0% vs 0.5% in Canada) or to
institutional care (16.8% vs 8.0% in Canada).19 In their
study, the median length of stay for AAA repair was 9.0 days
in Canada compared with 7.0 days in the United States. In
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 4 Tarride et al 785comparison, we observed median lengths of stay of 6 days
for EVAR and 11 days for OSR. Based on a relatively small
number of patients, previous evaluations of EVAR and
OSR in Canada have reported average lengths of stay of 5
days for EVAR and 11 days for OSR,18,20 which is also
consistent with our findings. Although our two groups had
comparable baseline characteristics and risk assessments (ie,
Leiden Score), more postoperative complications were ob-
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Fig 3. Incremental cost and effect pairs for endovascula
shown for (A) incremental costs and quality-adjusted life
gained. Each dot represents a bootstrap sample.served in the OSR group, leading to longer hospitaliza-tions, more ICU admissions, and higher hospitalization
costs. Despite the additional cost of the endograft, the
1-year health-related costs for EVAR patients were found
to be nearly identical to the costs for OSR patients.
On the basis of the point estimate, the EVAR treat-
ment group was found to be dominant in terms of cost-
effectiveness (ie, cheaper and more effective). However,
uncertainty regarding cost-effectiveness was found when
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October 2008786 Tarride et aldifferences between EVAR and OSR were not statistically
significant in terms of costs and QALYs, but a significant
mortality benefit effect was observed for EVAR.
The 1-year economic analysis indicated that if society or
decision makers were willing to pay $100,000/life-year
gained, the probability of EVAR being cost-effective was
0.9. Five-year extrapolations indicated that EVAR might be
cost-effective. However, the extrapolations do not account
for quality of life differences or cost-effects associated with
long-term comorbidities such as stroke, renal failure, and
myocardial infarction and therefore should be interpreted
accordingly. It is also important to note that this sensitivity
analysis was meant to extrapolate the 1-year mortality rates
observed in our trial conducted amongst high-risk patients.
As such, sensitivity analyses with different 1-year mortality
rates were not conducted. We did not consider scenarios
with different costs for endovascular devices for the initial
procedure or the reinterventions because we assumed that
the prices would remain constant.
Several limitations were associated with our study. This
prospective, nonrandomized study evaluated consecutive
patients and compared outcomes in patients with a high
surgical risk of death and postoperative complications. As
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Fig 4. Cost-effectiveness acceptability curves are shown for
(A) incremental costs per life-year (LY) gained and (B) incre-
mental cost per quality-adjusted life-year (QALY) gained.with all nonrandomized studies, there may be concernabout the comparability of treatment groups (ie, selection
bias). This concern was partially addressed through the risk
stratification of patients, and results indicated that the
baseline demographics, comorbidities, and Leiden scores
were similar between the two treatment groups. We also
adjusted for baseline utility values in our QALY calculations
to account for the nonrandomized aspect of the study.
The potential effect of anatomic suitability for EVAR
on outcomes was not examined within this study because
all patients treated with EVAR were anatomically suitable
for the procedure. Almost none of the OSR patients were
anatomically suitable for EVAR, which may limit the com-
parability of the results. Although the baseline characteris-
tics of our two groups were similar, our OSR patients might
have had a more complicated anatomy, which could also
explain the high mortality rate observed in the OSR group.
However, for these high-risk OSR patients willing to un-
dergo surgery and not anatomically suitable for EVAR,
OSR is the only available option. The relatively small num-
ber of patients in the OSR group compared with the EVAR
group remains a concern, but sampling variability was
addressed with nonparametric bootstrap techniques, and
cost-effectiveness acceptability curves were used to present
uncertainty.
The results may not be generalizable to lower-risk
patients or randomized clinical trials evaluating mixed-risk
patient populations, as are commonly found in published
economic studies comparing EVAR with OSR. In addition,
the results of the study are based on a single center in
Ontario, and this should be considered if results are to be
applied to other jurisdictions. LHSC was the primary refer-
ral center for EVAR in Ontario during the study period;
thus, the proportion of low- and high-risk patients ob-
served in our study may not reflect the case mix of other
hospitals in Canada or elsewhere.
Finally, patient recall was used to collect follow-up
information, which may have introduced some bias. Al-
though we evaluated the long-term costs and effects of
EVAR and OSR in high-risk patients, the 5-year extrapola-
tion results were based on point estimates and, as such,
these results should be interpreted with caution.
CONCLUSIONS
Despite these limitations, our results provide a second
insight in the cost-effectiveness of EVAR and OSR in
high-risk patients. Patients in this study were treated ac-
cording to current medical management of AAA patients at
LHSC, in which those at a low risk of surgery are treated
with OSR. As such, this cost-effectiveness analysis is not
comparable with previous economic evaluations that in-
cluded patients at low risk. In contrast to these studies, but
in agreement with results from Ireland,7 our results indi-
cated that EVAR may be a cost-effective strategy for pa-
tients at a high risk of surgical complications and anatomi-
cally suitable for EVAR. Follow-up is still being conducted
with the study participants, and the future analyses of
midterm outcomes will provide more information on the
JOURNAL OF VASCULAR SURGERY
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high-risk patients.
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